CWM
REGN icon

Compass Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Compass Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11
Closed -$6.98K – 347
2025
Q1 		$6.98K Hold
11
– – ﹤0.01% 367
2024
Q4 		$7.84K Hold
11
– – ﹤0.01% 352
2024
Q3 		$11.6K Hold
11
– – ﹤0.01% 345
2024
Q2 		$11.6K Hold
11
– – ﹤0.01% 348
2024
Q1 		$10.6K Hold
11
– – ﹤0.01% 347
2023
Q4 		$9.66K Hold
11
– – ﹤0.01% 342
2023
Q3 		$9.05K Hold
11
– – ﹤0.01% 351
2023
Q2 		$7.9K Hold
11
– – ﹤0.01% 366
2023
Q1 		$9.04K Hold
11
– – ﹤0.01% 366
2022
Q4 		$7.94K Buy
+11
New +$8.12K ﹤0.01% 364

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Compass Wealth Management's REGN Position: Q2 2025 in Review

Compass Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 11 shares — an estimated $6.98K sold.

Compass Wealth Management first reported a position in REGN in Q4 2022 and held it in 10 quarters. The position peaked at $11.6K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Compass Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Compass Wealth Management sold 11 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $6.98K.
  • Compass Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Compass Wealth Management's Regeneron Pharmaceuticals position peaked at $11.6K in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Compass Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.